Routine buyback disclosure with no new strategic information. The program is progressing as expected with ~56% of the authorization utilized. Monitor for any changes in execution pace or early completion announcements, but no immediate trading action warranted.
Price Chart
Executive Summary
Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyback program. Since the last announcement on August 17, 2026, the company repurchased 1,045,000 B shares for approximately DKK 308.8 million at an average price of ~DKK 295.50. The program is on track with DKK 8.39 billion spent out of the DKK 15 billion authorization. This is a routine capital allocation update with no material new information for traders.
Key Facts
- Novo Nordisk repurchased 1,045,000 B shares (Aug 17-21, 2026) for ~DKK 308.8 million at avg ~DKK 295.50/share
- Total repurchased under the program since Feb 4, 2026: 29,929,179 B shares at avg DKK 280.34 for DKK 8.39 billion
- Program authorization: up to DKK 15 billion over 12 months beginning Feb 4, 2026
- Company now holds 43,969,876 B shares as treasury shares, representing 1.0% of share capital
- Total share capital: 4,465,000,000 A and B shares including treasury shares
Financial Impact
DKK 308.8 million in share repurchases during the reported week; total program spend of DKK 8.39 billion against a DKK 15 billion authorization
Risk Factors
- No material risks identified in this routine filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005715 |
| Document: 0001171843-26-005715-index.html | 0001171843-26-005715 |
| Document: 0001171843-26-005715.txt | 0001171843-26-005715 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 5d ago | 6-K | $39.13 | awaiting T+20 | awaiting T+20 | $40.00 (+2.22%) |
Oct 26, 2026 6d ago | Court Ruling | $38.67 | awaiting T+20 | awaiting T+20 | $40.00 (+3.44%) |
Oct 19, 2026 12d ago | 6-K | $38.42 | awaiting T+20 | awaiting T+20 | $40.00 (+4.11%) |
Oct 13, 2026 18d ago | 6-K | $38.06 | awaiting T+20 | awaiting T+20 | $40.00 (+5.10%) |
Oct 6, 2026 25d ago | 6-K | $37.53 | awaiting T+20 | awaiting T+20 | $40.00 (+6.58%) |
Sep 28, 2026 4w ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $40.00 (+3.33%) |
Sep 23, 2026 5w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $40.00 (+3.57%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $40.00 (+0.50%) |
Sep 17, 2026 6w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $40.00 (−7.39%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $40.00 (−5.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers